沙申梅东对慢性支气管炎的影响:一种多方法方法
Wenchao Zhou1,2, Yaqin Hu2, Yun Qiu1,2
1TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Materia Medica Research Institute, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China.
沙申梅东 (SSMDD) 通过向干白素6 (IL-6) 来减少慢性支气管炎 (CB) 的炎症. 关键化合物奎尔丁和凯姆菲罗尔显著降低IL-6水平,验证了其治疗潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
- 免疫学 免疫学 免疫学
背景情况:
- 沙申梅东 (SSMDD) 是一种中国传统医学 (TCM) 的配方.
- 慢性支气管炎 (CB) 是一种严重的呼吸系统疾病.
- 洲际蛋白6 (IL-6) 是CB中一个关键的炎症调解剂.
研究的目的:
- 阐明SSMDD在慢性支气管炎 (CB) 中的抗炎机制.
- 确定SSMDD的活跃组件及其目标.
- 为了研究SSMDD对6 (IL-6) 介质蛋白表达的影响.
主要方法:
- 网络药理学用于预测活性化合物和标.
- 分子对接以评估结合亲和力.
- 转录基因分析,ELISA,以及用于机制验证的Western blot.
主要成果:
- 奎尔丁和凯姆菲罗尔被确定为向IL-6的关键活性成分.
- SSMDD证明了与炎症相关的途径的调节.
- 观察到IL-6水平的显著降低 (55%的奎尔塞丁,36%的凯姆菲罗尔) 和蛋白质表达 (33%的奎尔塞丁,25%的凯姆菲罗尔).
结论:
- 通过向IL-6,SSMDD在CB中发挥抗炎作用.
- 提供了对SSMDD治疗作用的机制性见解.
- 表明SSMDD在治疗其他炎症性疾病方面的潜力.
更多相关视频
05:56A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
Published on: May 12, 2023
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
